Opioid-Related Genetic Polymorphisms of Cytochrome P450 Enzymes after Total Joint Arthroplasty

The opioid epidemic: impact on orthopaedic surgery.

J Am Acad Orthop Surg. 23: 267-271Manchikanti L. Helm S. 2nd Fellows B. et al.

Opioid epidemic in the United States.

Pain Physician. 15: Es9-Es38Hansen R.N. Oster G. Edelsberg J. et al.

Economic costs of nonmedical use of prescription opioids.

Clin J Pain. 27: 194-202

CDC Grand Rounds: Prescription Drug Overdoses—a U.S. Epidemic.

JAMA. 307: 774-776Awad M.E. Padela M.T. Sayeed Z. et al.

Pharmacogenomics Testing for Postoperative Pain Optimization Before Total Knee and Total Hip Arthroplasty.

JBJS Rev. 6: e3

Patient satisfaction and total hip arthroplasty: a review.

Arthroplasty. 1: 6Neuprez A. Delcour J.P. Fatemi F. et al.

Patients’ Expectations Impact Their Satisfaction following Total Hip or Knee Arthroplasty.

PLoS ONE. 11: e0167911Baker P.N. van der Meulen J.H. Lewsey J. et al.

The role of pain and function in determining patient satisfaction after total knee replacement.

The Journal of Bone and Joint Surgery. British volume. 89-B: 893-900Awad M.E. Padela M.T. Sayeed Z. et al.

Pharmacogenomic Testing for Postoperative Pain Optimization Before Total Joint Arthroplasty: A Focus on Drug-Drug-Gene Interaction with Commonly Prescribed Drugs and Prior Opioid Use.

JBJS Rev. 7: e2

Opioid metabolism.

Mayo Clin Proc. 84: 613-624Agarwal D. Udoji M.A. Trescot A.

Genetic testing for opioid pain management: a primer.

Pain Ther. 6: 93-105

Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance.

J Pharm Pract. 20: 206-218Weckselblatt B. Rudd M.K.

Human Structural Variation: Mechanisms of Chromosome Rearrangements.

Trends Genet. 31: 587-599

Exploring the Impact of Single-Nucleotide Polymorphisms on Translation.

Front Genet. 9

Pharmacogenomics in clinical practice: reality and expectations.

P t. 36: 412-450

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation.

Pharmacol Ther. 138: 103-141

Database, C.D. Free U.S. Outpatient Drug Usage Statistics. 2021 [cited 2021 January 14].

()Whirl-Carrillo M. McDonagh E.M. Hebert J.M. et al.

Pharmacogenomics knowledge for personalized medicine.

Clin Pharmacol Ther. 92: 414-417Sangar M.C. Anandatheerthavarada H.K. Martin M.V. et al.

Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting.

Mol Genet Metab. 99: 90-97Andreassen T.N. Eftedal I. Klepstad P. et al.

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.

Eur J Clin Pharmacol. 68: 55-64VanderVaart S. Berger H. Sistonen J. et al.

CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.

Ther Drug Monit. 33: 425-432Susce M.T. Murray-Carmichael E. de Leon J.

Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.

Prog Neuropsychopharmacol Biol Psychiatry. 30: 1356-1358Zineh I. Beitelshees A.L. Gaedigk A. et al.

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.

Clin Pharmacol Ther. 76: 536-544de Leon J. Dinsmore L. Wedlund P.

Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.

J Clin Psychopharmacol. 23: 420-421Elkalioubie A. Allorge D. Robriquet L. et al.

Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer.

Eur J Clin Pharmacol. 67: 855-858Stamer U.M. Stüber F. Muders T. et al.

Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication.

Anesth Analg. 107: 926-929Vevelstad M. Pettersen S. Tallaksen C. et al.

O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.

Eur J Clin Pharmacol. 65: 795-801Kirksey M. Chiu Y.L. Ma Y. et al.

Trends in in-hospital major morbidity and mortality after total joint arthroplasty: United States 1998-2008.

Anesth Analg. 115: 321-327Pulido L. Parvizi J. Macgibeny M. et al.

In hospital complications after total joint arthroplasty.

J Arthroplasty. 23: 139-145Belmont Jr., P.J. Goodman G.P. Kusnezov N.A. et al.

Postoperative myocardial infarction and cardiac arrest following primary total knee and hip arthroplasty: rates, risk factors, and time of occurrence.

J Bone Joint Surg Am. 96: 2025-2031Fleischmann K.E. Goldman L. Young B. et al.

Association between cardiac and noncardiac complications in patients undergoing noncardiac surgery: outcomes and effects on length of stay.

Am J Med. 115: 515-520Edelstein A.I. Kwasny M.J. Suleiman L.I. et al.

Can the American College of Surgeons Risk Calculator Predict 30-Day Complications After Knee and Hip Arthroplasty?.

J Arthroplasty. 30: 5-10Fleisher L.A. Beckman J.A. Brown K.A. et al.

ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery.

Circulation. 116: e418-e499van Klei W.A. Bryson G.L. Yang H. et al.

Effect of beta-blocker prescription on the incidence of postoperative myocardial infarction after hip and knee arthroplasty.

Anesthesiology. 111: 717-724Bijl M.J. Visser L.E. van Schaik R.H. et al.

Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.

Clin Pharmacol Ther. 85: 45-50Ciszkowski C. Madadi P. Phillips M.S. et al.

Codeine, ultrarapid-metabolism genotype, and postoperative death.

N Engl J Med. 361: 827-828Batty J.A. Hall A.S. White H.L. et al.

An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.

Clin Pharmacol Ther. 95: 321-330Hamadeh I.S. Langaee T.Y. Dwivedi R. et al.

Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.

Clin Pharmacol Ther. 96: 175-181Shord S.S. Cavallari L.H. Gao W. et al.

The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.

Eur J Clin Pharmacol. 65: 651-658Lotsch J. Rohrbacher M. Schmidt H. et al.

Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?.

Pain. 144: 119-124Takekuma Y. Takenaka T. Kiyokawa M. et al.

Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.

Biol Pharm Bull. 30: 537-542Bijl M.J. Visser L.E. Hofman A. et al.

Influence of the CYP2D6∗4 polymorphism on dose, switching and discontinuation of antidepressants.

Br J Clin Pharmacol. 65: 558-564Van Nieuwerburgh F.C. Denys D.A. Westenberg H.G. et al.

Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms.

Int J Psychiatry Clin Pract. 13: 345-348Wijnen P.A. Limantoro I. Drent M. et al.

Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity.

Ann Clin Biochem. 46: 527-530Nickinson R.S. Board T.N. Kay P.R.

Post-operative anxiety and depression levels in orthopaedic surgery: a study of 56 patients undergoing hip or knee arthroplasty.

J Eval Clin Pract. 15: 307-310Scott J.E. Mathias J.L. Kneebone A.C.

Depression and anxiety after total joint replacement among older adults: a meta-analysis.

Aging Ment Health. 20: 1243-1254Dharmshaktu P. Tayal V. Kalra B.S.

Efficacy of antidepressants as analgesics: a review.

J Clin Pharmacol. 52: 6-17de Vos A. van der Weide J. Loovers H.M.

Association between CYP2C19∗17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.

Pharmacogenomics J. 11: 359-367

Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity.

J Med Toxicol. 7: 220-223Mazaleuskaya L.L. Theken K.N. Gong L. et al.

PharmGKB summary: ibuprofen pathways.

Pharmacogenet Genomics. 25: 96-106Parvizi J. Miller A.G. Gandhi K.

Multimodal pain management after total joint arthroplasty.

J Bone Joint Surg Am. 93: 1075-1084

Perioperative administration of selective cyclooxygenase-2 inhibitors for postoperative pain management in patients after total knee arthroplasty.

J Arthroplasty. 28: 207-213.e2Llerena A. Alvarez M. Dorado P. et al.

Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain.

Pharmacogenomics J. 14: 229-234Pilotto A. Seripa D. Franceschi M. et al.

Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.

Gastroenterology. 133: 465-471Prieto-Perez R. Ochoa D. Cabaleiro T. et al.

Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.

J Clin Pharmacol. 53: 1261-1267Bae J.W. Forslund-Bergengren C. Tybring G. et al.

Effects of CYP2C9∗1/∗3 and ∗1/∗13 on the pharmacokinetics of losartan and its active metabolite E-3174.

Int J Clin Pharmacol Ther. 50: 683-689Liang R. Li L. Li C. et al.

Impact of CYP2C9∗3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.

J Thromb Thrombolysis. 34: 120-125Mega J.L. Walker J.R. Ruff C.T. et al.

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Lancet. 385: 2280-2287Lee J.E. Ryu D.H. Jeong H.J. et al.

Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9∗1/∗3 and thyrotoxicosis.

J Korean Med Sci. 29: 1317-1319Kim H.S. Lee S.S. Oh M. et al.

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.

Pharmacogenet Genomics. 19: 103-112Andersson M.L. Eliasson E. Lindh J.D.

A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9∗3 allele.

Pharmacogenomics. 13: 757-762

Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.

. 9

Bupropion and other non-nicotine pharmacotherapies.

Bmj. 328: 509-511Tomaz P.R. Santos J.R. Issa J.S. et al.

CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.

Eur J Clin Pharmacol. 71: 1067-1073Levran O. Peles E. Hamon S. et al.

CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.

Addict Biol. 18: 709-716Remerand F. Le Tendre C. Baud A. et al.

The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study.

Anesth Analg. 109: 1963-1971Adam F. Chauvin M. Du Manoir B. et al.

Small dose ketamine improves postoperative analgesia and rehabilitation after total knee arthroplasty.

Anesth Analg. 100: 475-480Li Y. Jackson K.A. Slon B. et al.

CYP2B6∗6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects.

Br J Clin Pharmacol. 80: 276-284

CYP2B6 genotype guided dosing of propofol anesthesia in the elderly based on nonparametric population pharmacokinetic modeling and simulations.

Int J Clin Pharmacol Toxicol. 6: 242-249Loryan I. Lindqvist M. Johansson I. et al.

Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia.

Eur J Clin Pharmacol. 68: 397-406

Perioperative abstinence from cigarettes: physiologic and clinical consequences.

Anesthesiology. 104: 356-367Bedard N.A. DeMik D.E. Dowdle S.B. et al.

Trends and risk factors for prolonged opioid use after unicompartmental knee arthroplasty.

Bone Joint J. 100-b: 62-67Johnstone E. Benowitz N. Cargill A. et al.

Determinants of the rate of nicotine metabolism and effects on smoking behavior.

Clin Pharmacol Ther. 80: 319-330Guengerich F.P. Hosea N.A. Parikh A. et al.

Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs.

Drug Metab Dispos. 26: 1175-1178Li A.P. Kaminski D.L. Rasmussen A.

Substrates of human hepatic cytochrome P450 3A4.

Toxicology. 104: 1-8Lown K.S. Bailey D.G. Fontana R.J. et al.

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.

J Clin Invest. 99: 2545-2553Bhatnagar V. Garcia E.P. O’Connor D.T. et al.

CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.

Am J Nephrol. 31: 95-103

Functional gene variants of CYP3A4.

Clin Pharmacol Ther. 96: 340-348Kitzmiller J.P. Luzum J.A. Baldassarre D. et al.

CYP3A4∗22 and CYP3A5∗3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.

Pharmacogenet Genomics. 24: 486-491Min D.I. Ku Y.M. Perry P.J. et al.

Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.

Transplantation. 62: 123-125Shi W.L. Tang H.L. Zhai S.D.

Effects of the CYP3A4∗1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis.

PLoS One. 10: e0127995Ishikawa Y. Akiyoshi T. Imaoka A. et al.

Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin.

Biopharm Drug Dispos. 38: 420-425Foti R.S. Rock D.A. Wienkers L.C. et al.

Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.

Drug Metab Dispos. 38: 981-987Tateishi T. Krivoruk Y. Ueng Y.F. et al.

Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation.

Anesth Analg. 82: 167-172Yuan R. Zhang X. Deng Q. et al.

Impact of CYP3A4∗1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery.

Clinica Chim Acta. 412: 755-760Kapur B.M. Hutson J.R. Chibber T. et al.

Methadone: a review of drug-drug and pathophysiological interactions.

Crit Rev Clin Lab Sci. 48: 171-195Chen C.H. Wang S.C. Tsou H.H. et al.

Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients.

Pharmacogenomics. 12: 1397-1406

Calcium channel blockers in treatment of hypertension.

Prog Cardiovasc Dis. 44: 207-216Wang X.F. Yan L. Cao H.M. et al.

Effect of CYP3A4∗1G, CYP3A5∗3, POR∗28, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers.

Int J Clin Pharmacol Ther. 53: 737-745

CYP3A4∗1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.

Eur J Clin Pharmacol. 64: 877-882Danielak D. Karaźniewicz-Łada M. Wiśniewska K. et al.

Impact of CYP3A4∗1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel.

Eur J Drug Metab Pharmacokinet. 42: 99-107Kapoor R. Tan-Koi W.C. Teo Y.Y.

Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.

Eur J Hum Genet. 24: 1651-1657Bartlett G. Zgheib N. Manamperi A. et al.

Pharmacogenomics in Primary Care: A Crucial Entry Point for Global Personalized Medicine?.

Curr Pharmacogenomics Person Med. 10: 101-105Volkow N.D. McLellan A.T.

Opioid abuse in chronic pain--misconceptions and mitigation strategies.

N Engl J Med. 374: 1253-1263Cregg R. Russo G. Gubbay A. et al.

Pharmacogenetics of analgesic drugs.

Br J Pain. 7: 189-208Di Francia R. Berretta M. Catapano O. et al.

Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications.

Clin Chem Lab Med. 49: 1105-1111

留言 (0)

沒有登入
gif